Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 3/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16733050 | 1.00 | TACR1 (0.43) | TACR1MEN1KMT2ARORCMMP13 | |
| SCHEMBL5973099 | 0.89 | RORC (0.40) | TACR1KMT2ARORCGPR119HSD17B10 | |
| SCHEMBL7475696 | 0.89 | RORC (0.40) | TACR1KMT2ARORCGPR119HSD17B10 | |
| SCHEMBL14343619 | 0.88 | RORC (0.46) | TACR1RORCGPR119GRM5 | |
| SCHEMBL4198304 | 0.88 | RORC (0.46) | TACR1RORCGPR119GRM5 | |
| SCHEMBL1595217 | 0.88 | RORC (0.46) | TACR1RORCGPR119GRM5 | |
| SCHEMBL830155 | 0.88 | RORC (0.46) | TACR1RORCGPR119GRM5 | |
| SCHEMBL15185071 | 0.88 | RORC (0.46) | TACR1RORCGPR119GRM5 | |
| SCHEMBL2299757 | 0.88 | RORC (0.46) | TACR1RORCGPR119GRM5 | |
| SCHEMBL29063356 | 0.88 | RORC (0.46) | TACR1RORCGPR119GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9718840-B2 | Condensed 5-oxazolidinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-9718840-B2 | Condensed 5-oxazolidinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-9718840-B2 | Condensed 5-oxazolidinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-20170022218-A1 | CONDENSED 5-OXAZOLIDINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-01-26 | — | — | US | disclosed |
| US-20170022218-A1 | CONDENSED 5-OXAZOLIDINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-01-26 | — | — | US | disclosed |
| US-20170022218-A1 | CONDENSED 5-OXAZOLIDINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-01-26 | — | — | US | disclosed |
| EP-3095786-A1 | CONDENSED 5-OXAZOLIDINONE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2016-11-23 | — | — | EP | disclosed |
| CN-106103453-A | It is condensed 5 oxazolidinone derivatives | 大日本住友制药株式会社 | 2016-11-09 | — | — | CN | disclosed |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| WO-2015107724-A1 | CONDENSED 5-OXAZOLIDINONE DERIVATIVE | 大日本住友製薬株式会社 | 2015-07-23 | — | — | WO | disclosed |
| EP-2876105-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2015-05-27 | — | — | EP | disclosed |
| EP-2876105-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2015-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | RB1, F2, SFPQ | TACR1 4433/4885MEN1 3514/4885KMT2A 484/4885 |
| US-20170022218-A1 | CONDENSED 5-OXAZOLIDINONE DERIVATIVE | F2, SERPINC1, F12 | TACR1 3765/4885MEN1 843/4885KMT2A 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.